Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
  • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/20—Bacteria; Culture media therefor
  • C12N1/205—Bacterial isolates
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P19/00—Preparation of compounds containing saccharide radicals
  • C12P19/44—Preparation of O-glycosides, e.g. glucosides
  • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
  • C12R2001/00—Microorganisms ; Processes using microorganisms
  • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
  • C12R2001/045—Actinoplanes

Definitions

• Multidrug-resistant strains of many clinically important pathogenic bacteria including methicillin-resistant Staphylococcus aureus (MRSA),
• the present invention relates to a novel antibiotic compound, nocathiacin 6- deoxyglucoside, and comprising a process for preparing it by fermentation of nocathiacin I with Actinoplanes sp. ATCC 53771 or Amycolata autotrophica ATCC 35204 or mutants thereof.
• Nocathiacin biotransformation product described herein exhibits potent antimicrobial activity against Gram-positive bacteria in vitro, and exhibits in v ivo efficacy in a systemic Staph. aureus infection model in animals.
• Nocathiacin 6-deoxyglucoside and its precursor nocathiacin I are antibiotics useful in the treatment of bacterial infections in humans.
• the nocathiacin antibiotics of this invention are derived from nocathiacin I, a novel fermentation product previously described by J. E. Leet et al (U. S. Provisional Patent Application Serial No. 60/093,021 filed July 16, 1998) and Sasaki, T. et al, /. of Antibiotics 51, No. 8, pp. 715-721 (1998).
• the nocathiacin antibiotics are related to but clearly distinguishable from nosiheptide (Prange T. et al, ⁇ . Am Chem Soc. 99, 6418 (1977); Benazet, F. et. al. Experientia 36, 414 (1980); Floss, H. G. et al, J. Am Chem Soc.
• the invention concerns novel derivatives of nocathiacin antibiotic I, and others produced by biotransformation and having the structural formula below:
• W is anc
• R is H
• X is H (for nocathiacin II 6- deoxyglycoside);
• W is H and R is OH,
• X is H (for nocathiacin III 6- deoxyglycoside);
• W is and R is OH,
• X is F for fluoronocathiacin I 6-deoxyglycoside.
• the nocathiacin derivatives are obtained by the fermentation of
• the biotransformation process is accomplished under submerged aerobic conditions in an aqueous medium containing carbon and nitrogen nutrient at a pH of about 5-8 for a sufficient time to produce nocathiacin 6- deoxyglycoside.
• the resulting analogs exhibit antibiotic activity against a broad spectrum of Gram-positive bacteria, and have improved solubility in aqueous solutions compared to nocathiacin I.
• analogs of nocathiacin II and III are prepared.
• the invention also deals with pharmaceutical compositions and methods for treating bacterial infections with the nocathiacin antibiotic derivatives, as well as a biologically pure culture of Actinoplanes sp. ATCC 53771 or Amycolata autotreophica ATCC 35204 from which the antibiotic is obtained.
• the invention includes all pharmaceutically acceptable derivatives of the nocathiacin 6-deoxyglycoside antibiotics, such as the salts and esters thereof.
• the utility of the subject compounds in the treatment of bacterial infections is based upon the expectation that compounds which inhibit Gram-positive bacteria in vitro and in vivo can be used as antibiotics in animals, and in particular, humans.
• the compounds of this invention were found to have antibiotic activity, particularly in inhibiting the growth of Gram-positive bacteria.
• the present invention describes novel derivative of nocathiacin antibiotics obtained through microbial biotransformation.
• the invention provides an efficient method for the preparation of nocathiacin 6- deoxyglycoside from nocathiacin.
• the novel process of this invention comprises fermentation of Actinoplanes sp. ATCC 53771, Amycolata autotrophica ATCC 35204, or mutants thereof in the presence of substrate nocathiacin I in a nutrient medium, and isolation of the resulting biotransformation product, nocathiacin 6-deoxyglycoside, in a conventional manner.
• Nocathiacin I has the structural formula below (i.e., W is the glycoside instead of H; R is OH; and X is H).
• Nocathiacin II is the same as I, except R is H.
• W is H; R is OH; and X is H.
• the microorganisms, Actinoplanes sp. ATCC 53771 and Amycolata autotrophica ATCC 35204, employed in the present invention may be any microorganism capable of converting nocathiacin to nocathiacin 6- deoxyglycoside.
• the microorganism regardless of origin or purity, may be employed in the free state or immobilized on a support such as by physical adsorption or entrapment.
• the preferred biotransformation microorganisms that were used in this study for conversion of nocathiacin to nocathiacin 6-deoxyglucoside were obtained from American Type Culture Collection.
• the taxonomic analysis of Actinoplanes sp. ATCC 53771 has been described in U.S. Patent 4,981,792 (January 1, 1991).
• the taxonomic analysis of Amycolata autotrophica ATCC 35204 has been described in J. Antibiotics 36: 1176-1183, 1983.
• nocathiacin 6-deoxyglycoside can be produced by culturing the aforementioned microorganism in the presence of an appropriate concentration of substrate nocathiacin in an aqueous nutrient medium containing sources of assimilable carbon and nitrogen, preferably under submerged aerobic conditions.
• the aqueous medium is incubated at a temperature between 26°C and 32°C, preferably at 28°C.
• the aqueous medium is incubated for a period of time necessary to complete the biotransformation as monitored by high pressure liquid chromatography (HPLC) usually for a period of about 20-48 hours after the addition of the substrate, on a rotary shaker operating at about 250 rpm with a throw of about 2 inches.
• HPLC high pressure liquid chromatography
• microorganisms may be achieved by one of ordinary skill of the art by the use of appropriate medium.
• Appropriate media for growing microorganism include those which provide nutrients necessary for the growth of microbial cells.
• a typical medium for growth includes necessary carbon sources, nitrogen sources, and trace elements.
• Inducers may also be added.
• inducer as used herein, includes any compound enhancing formation of the desired enzymatic activity within the microbial cell.
• Carbon sources may include sugars such as glucose, fructose, gaiactose, maltose, sucrose, mannitol, sorbital, glycerol starch and the like; organic acids such as sodium acetate, sodium citrate, and the like; and alcohols such as ethanol, propanol and the like.
• Nitrogen sources may include N-Z amine A, corn steep liquor, soybean meal, beef extract, yeast extract, tryptone, peptone, cottonseed meal, peanut meal, amino acids such as sodium glutamate and the like, sodium nitrate, ammonium sulfate and the like.
• Trace elements may include magnesium, manganese, calcium, cobalt, nickel, iron, sodium and potassium salts. Phosphates may also be added in trace or preferably, greater than trace amounts.
• the medium employed may include more than one carbon or nitrogen source or other nutrient.
• Preferred media for growth include aqueous media, particularly that described in the example herein.
• nocathiacin 6-deoxyglucoside can be recovered from the culture medium by conventional means which are commonly used for the recovery of other known biologically active substances. Accordingly nocathiacin 6-deoxyglycoside can be obtained upon extraction of the culture with a conventional solvent, such as ethyl acetate, treatment with a conventional resin (e.g. anion or cation exchange resin, non-ionic adsorption resin), treatment with a conventional adsorbent (e.g. activated charcoal, silica gel, cellulose, alumina), crystallization, recrystallization, and /or purification by reverse phase preparative HPLC.
• a conventional solvent such as ethyl acetate
• a conventional resin e.g. anion or cation exchange resin, non-ionic adsorption resin
• a conventional adsorbent e.g. activated charcoal, silica gel, cellulose, alumina
• Actinoplanes sp. ATCC 53771 or Amycolata autotrophica ATCC 35204 can be used as the biotransformation host to convert nocathiacin to a novel product, nocathiacin 6-deoxyglycoside.
• the biotransformation process utilizing Actinoplanes sp. ATCC 53771 as the biotransformation host is shown in Example 1 below.
• the example of using Amycolata autotrophica ATCC 35204 as the biotransformation host for the conversion of nocathiacin to nocathiacin 6-deoxyglycoside is as follows.
• the biotransformation cultures were incubated at 28°C on a rotary shaker operating at 250 rpm for 48 hours. Four hundred and twenty mg nocathiacin in 63 ml DMSO was then distributed equally into the biotransformation cultures (1.5 ml/culture). The cultures were then returned to the shaker and incubated for additional 28 hours at 28°C and 250 rpm. The cultures were then processed for the recovery of the nocathiacin analog. Isolation and structural characterization
• nocathiacin antibiotic biotransformation products from either Actinoplanes sp. ATCC 53771 or Amycolata autotrophica ATCC 35204 using nocathiacin as a substrate was monitored using C18 HPLC-UV. Extraction with ethyl acetate, followed by solvent partitioning, yielded a complex of nocathiacin biotransformation products. Final purification of the individual components was accomplished by reverse phase (C18) preparative HPLC. Spectral data indicated that the compounds are derivatives of the substrate, nocathiacin.
• Hexanes, chloroform, (anhydrous ACS grade), and methanol, acetonitrile (anhydrous HPLC grade) were obtained from the Fisher Scientific Company. These solvents were not repurified or redistilled.
• Water used in chromatography experiments refers to in-house deionized water passed through a Millipore 4 cartridge reagent grade water system (10 mega ohm Milli-Q water).
• nocathiacin compounds herein When employed as pharmaceutical compositions for the treatment of bacterial infections, they may be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium.
• Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
• the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
• active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes.
• Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired.
• Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
• active compounds may also be administered parenterally or intraperitoneally.
• Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
• Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
• the term pharmaceutically acceptable salt includes solvates, hydrates, acid addition salts and quaternary salts.
• the acid addition salts are formed from a nocathiacin compound having a basic nitrogen and a pharmaceutically acceptable inorganic or organic acid including but not limited to hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, citric, malonic, succinic, fumeric, maleic, sulfamic, or tartaric acids.
• Quaternary salts are formed from a basic nocathiacin compound and an alkyl or arylalkyl halide, preferably methyl or benzyl bromide.
• halogen refers to bromine, chlorine, fluorine or iodine.
• the culture was incubated at 28°C on a rotary shaker operating at 250 rpm for 47 hours.
• the resulting culture from four flasks was pooled and 10 ml of this culture was used to inoculate each of the thirty 500-ml flasks containing the biotransformation medium with the following per liter of deionized water: Glucose, 10 g; HY-case SF, 2 g; beef extract, 1 g; corn steep liquor, 3 g.
• the biotransformation cultures were incubated at 28°C on a rotary shaker operating at 250 rpm for 23 hours.
• nocathiacin I Three hundred mg nocathiacin I in 45 ml DMSO was then distributed equally into the biotransformation cultures (1.5 ml per culture). The cultures were then returned to the shaker and incubated for additional 48 hours at 28°C and 250 rpm. The cultures were then processed for the recovery of the nocathiacin analog.
• Fermentation broth of Actinoplanes sp. ATCC 53771 (3 L.) was extracted (whole broth including mycelia) with approximately 1.5 L. ethyl acetate by vigorous shaking. The biphasic mixture was vacuum filtered through a pad of dicalite. The phases were separated and the lower, aqueous portion extracted two additional times with 1.0 L ethyl acetate. The pale yellow ethyl acetate extracts were pooled and evaporated in vacuo to dryness in a rotary evaporator to yield approximately 240 mg of Residue A.
• Residue A (240 mg) was dissolved in 20 ml of 10% water in methanol. The solution was transferred to a separatory funnel and extracted 3 times with an equal volume of hexane. The hexane layer was removed. The aqueous methanol phase was diluted to 35% water in methanol by adding 7.6 ml of water and extracted 3 times with an equal volume of chloroform. The chloroform had been previously saturated with 35% water in methanol. The hexane, chloroform, and aqueous methanol extracts were evaporated to dryness in vacuo in a rotary evaporator. Nocathiacin antibiotics were detected primarily in the chloroform fraction, (Residue B, 204 mg). Isolation of Nocathiacin 6-deoxyglycoside:
• Residue B was further purified using the specified Beckman System Gold preparative HPLC system; Rainin C18 column. A typical sample injection size was 50 mg/100 ⁇ l DMSO. Elution was begun with 0.1M ammonium acetate-acetonitrile 55:45 v/v with a 30 minute linear gradient to acetonitrile. Elution flow rate was 10 ml/min. Detection (UV) was at 290 nm. In this manner, nocathiacin 6-deoxyglycoside (14 minute peak, 36 mg total yield) was obtained.
• Nocathiacin 6-deoxyglycoside (20.1 mg; 0.0127 mmol) was mixed with 100 ⁇ l MeOH and dissolved in 1 ml tetrahydrofuran. To the suspension was added 1 equivalent 0.1N HC1 (127 ⁇ l). After 5 minutes, the resulting clear solution was evaporated, resuspended in water and lyophilized.
• Infrared Spectrum Major IR Bands (cm -1 ) 3383, 2929, 1719, 1662, 1533, 1478, 1434, 1384, 1319, 1251, 1208, 1162, 1129, 1089, 1035, 1000, 952, 886, 806, 746.
• Circular Dichroism CD ⁇ nm ( ⁇ ) (MeOH) 212 (+15.4), 239 (-59.3), 268 (+28.4), 305 (-11.4), 349 (+11.6).
• Formula Weight 1618 Infrared Spectrum: Major IR Bands (cm '1 ) 3384, 2929, 1719, 1662,
• the culture was incubated at 28°C on a rotary shaker operating at 250 rpm for 44.5 hours.
• the resulting culture from eight flasks was pooled and 10 ml of this culture was used to inoculate each of the fifty 500-ml flasks containing the medium with the following per liter of deionized water: Glucose, 10 g; HY-case SF, 2 g; beef extract, 1 g; corn steep liquor, 3 g.
• the cultures were incubated at 28°C on a rotary shaker operating at 250 rpm for 24.5 hours.
• the culture was pooled and distributed into six 1 L centrifuge bottles at approximately equal volume.
• the sixth flask was incubated at 28°C and 200 rpm for 8.5 hours and an additional 200 mg nocathiacin I in 20 ml DMSO was added. After 18 hours, 12 g dextrose was added and the flask was incubated at 28°C and 250 rpm for 1 day before processing for the recovery of the nocathiacin analogs.
• the above reaction mixture (2.4 L.) was extracted (whole broth including mycelia) with approximately 2.4 L. ethyl acetate by vigorous shaking.
• the biphasic mixture was vacuum filtered through a pad of dicalite.
• the phases were separated and the lower, aqueous portion extracted one additional time with 2 L. ethyl acetate.
• the mycelia-dicalite cake was extracted with 1.6 L. ethyl acetate, followed by 1.5 L. chloroform- methanol.
• the pale yellow ethyl acetate and chloroform-methanol extracts were pooled, dissolved in 35% water in methanol (300 ml) and extracted twice with equal volumes chloroform.
• the chloroform had been previously saturated with 35% water in methanol.
• the chloroform extract was evaporated in vacuo to dryness in a rotary evaporator to yield approximately 3.4 g of Residue C.
• Residue D was further purified using the specified Beckman System Gold preparative HPLC system: YMC-Pack Pro C18 column (5 ⁇ particle size, 120 A pore size, 20 mm i.d. x 150 mm 1.), fitted with a ODS-A 25 ⁇ particle size, 120 A pore size, 10 mm i.d. x 10 mm 1. drop-in guard module.
• a typical sample injection size was 65 mg/300 ⁇ l DMSO. Elution was begun with 0.1M ammonium acetate-acetonitrile 55:45 v/v with a 30 minute concave gradient to acetonitrile. Elution flow rate was 10 ml/min. Detection (UV) was at 360 nm. In this manner, nocathiacin I 6- deoxyglycoside (14 minute peak, 267 mg total yield) and nocathiacin II 6- deoxyglycoside (6 minute peak, 10 mg total yield) were obtained.
• ESI-MS/MS fragmentation ions m/z 1421, 1396, 1250, 1232, 1206, 1188, 1171, 1139, 788
• Infrared Spectrum Major IR Bands (cm 1 ) 3382, 3119, 2934, 1728, 1664, 1533, 1481, 1435, 1385, 1318, 1251, 1193, 1131, 1091, 1076, 1000, 969, 794, 752
• Circular Dichroism CD ⁇ nm ( ⁇ ) (MeOH) 237 (-33.0), 256 (+12.3), 281sh (+8.9), 306 (-7.9), 350 (+5.2).
• the cell was suspended in potassium phosphate buffer (100 mM, pH 7.0) with 50 g/L dextrose to a final volume of 220 ml in a 500-ml flask. To this mixture, 1.1 ml of 20% NH 4 C1 was added. One hundred and eight mg nocathiacin III in 10 ml DMSO was added to the above cell suspension and the reaction mixture was then incubated at 28°C and 200 rpm for 2 days. The reaction mixture was extracted three times each with 200 ml ethyl acetate. The combined ethyl acetate extracts were evaporated to dryness.
• potassium phosphate buffer 100 mM, pH 7.0
• Residue E was further purified using the specified Beckman System Gold preparative HPLC system: YMC-Pack ODS-AQ column (10 ⁇ particle size, 120 A pore size, 20 mm i.d. x 150 mm L), fitted with a ODS-A 25 ⁇ particle size, 120 A pore size, 10 mm i.d. x 10 mm 1. drop-in guard module. Elution was begun with 0.1M ammonium acetate-acetonitrile 55:45 v/v with a 30 minute linear gradient to acetonitrile. Elution flow rate was 10 ml/min. Detection (UV) was at 290 nm. In this manner, nocathiacin III 6- deoxyglycoside (7 minute peak, 3 mg total yield) was obtained.
• Reaction Culture From the frozen vegetative stock culture of Actinoplanes sp. ATCC
• the cell was suspended in potassium phosphate buffer (100 mM, pH 7.0) with 50 g/L dextrose to a final volume of 250 ml in a 500-ml flask. To this mixture, 1.1 ml of 20% NH 4 C1 was added. Seventy ml of the above cell suspension was transferred to a 500-ml flask and 32 mg 5- fluoronocathiacin I in 4 ml DMSO was then added to the above cell
• Residue F was further purified using the specified Beckman System Gold preparative HPLC system: YMC-Pack ODS-AQ column (10 ⁇ particle
• MIC minimum inhibitory concentration
• Streptococcus A27881 0.001 0.001 0.007 ⁇ 0.0005 ⁇ 0.0005 pneumoniae/ penicillin intermediate
• Streptococcus A28272 0.001 0.001 0.007 ⁇ 0.0005 ⁇ 0.0005 pneumoniae/ penicillin resistant
• Enterococcus SC15829 0.5 0.125 faecium /thios trepton resistant (10 ug/ml)
• Staphylococc A15090 0.03 0.03 0.5 0.03 0.125 us aureus + 50% calf serum
• Staphylococc A24548 0.03 0.015 0.5 0.015 0.125 us epidermidis
• EXAMPLE 6 Nocathiacin 6-deoxyglycoside in vivo Antibiotic Activity in a Systemic Staph. aureus Infection Model.
• Nocathiacin 6-deoxyglycoside was evaluated for antibiotic activity in vivo, in a systemic infection model using female ICR mice.
• the animals were infected IP with 6.5 x 10 6 CFU of an overnight culture of
• Nocathiacin 6- deoxyglycoside was dissolved in a test formulation consisting of 10% DMSO, 5% Tween 80 and 85% water. The solution was administered SC at 100 mg/kg total dose (2 x 50 mg/kg doses at 1 and 4 hours post- infection). Nine out of nine animals survived the duration of the experiment with no signs of toxicity. The PD 50 of nocathiacin 6- deoxyglycoside was determined to be 6.2 mg/kg.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Oncology (AREA)
• Microbiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• General Engineering & Computer Science (AREA)
• Communicable Diseases (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Biomedical Technology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Saccharide Compounds (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=22273846

Family Applications (1)

Country Status (5)

Families Citing this family (2)

Family Cites Families (2)

• 1999
  • 1999-09-02 EP EP99945472A patent/EP1109820A4/de not_active Withdrawn
  • 1999-09-02 WO PCT/US1999/020242 patent/WO2000014100A1/en not_active Application Discontinuation
  • 1999-09-02 AU AU58064/99A patent/AU5806499A/en not_active Abandoned
  • 1999-09-02 JP JP2000568858A patent/JP2002524466A/ja active Pending
  • 1999-09-02 CA CA002342862A patent/CA2342862A1/en not_active Abandoned

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events